Clicky

Shanghai Junshi Biosciences Co Ltd(688180)

Description: Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.


Keywords: Biotechnology Biopharmaceutical Life Sciences Disease Infectious Diseases Antibodies Monoclonal Antibodies Rheumatoid Arthritis Psoriasis Melanoma Hepatocellular Carcinoma Biosimilar Non Small Cell Lung Carcinoma Spondylitis Monoclonal Antibody Therapy Soft Tissue Sarcoma Hyperlipidemia Humanized Antibody Humira Avastin Nasopharyngeal Carcinoma Esophageal Squamous Cell Carcinoma Js001 Js501 Mucosal Melanoma The Disease Treatment Of Covid 19 Triple Negative Breast Carcinoma Ubp1211 Urothelial Carcinoma

Home Page: www.junshipharma.com

Building 7
Shanghai, 200126
China
Phone: 86 21 6105 8800


Officers

Name Title
Mr. Jun Xiong Exec. Chairman
Dr. Ning Li Co-CEO, GM & Exec. Director
Mr. Cong Li Co-CEO & Exec. Director
Mr. Baohong Xu Financial Director
Dr. Hui Feng Chief Operations Officer & Exec. Director
Mr. Zhuobing Zhang Deputy GM & Exec. Director
Dr. Sheng Yao Deputy GM, Sr. VP of TopAlliance & Exec. Director
Ms. Lu Yuan Assistant to GM & Chief of Internal Audit Department
Mr. Xin Duan Deputy Gen. Mang.
Mr. Gang Wang Chief Quality Officer & Deputy GM

Exchange: SHG

Country: CN

Currency: Renminbi (¥)

Forward PE: 909.0909
Trailing PE: 0
Price-to-Book MRQ: 8.503
Price-to-Sales TTM: 23.5342
IPO Date:
Fiscal Year End: December
Full Time Employees: 2805
Back to stocks